tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

GSK and iTeos Advance Immunotherapy Study for Lung Cancer

GSK and iTeos Advance Immunotherapy Study for Lung Cancer

GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)), Iteos Therapeutics, Inc. ((ITOS)) announced an update on their ongoing clinical study.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

GlaxoSmithKline (GSK) and iTeos Therapeutics are conducting a Phase 2 study titled A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer. The study aims to evaluate the efficacy and safety of novel immunotherapy combinations compared to monotherapy in patients with high PD-L1 expression in advanced non-small cell lung cancer (NSCLC). This research is significant as it explores potential new treatments for a challenging cancer type.

The study tests several interventions, including pembrolizumab and dostarlimab as monotherapies, and combinations involving dostarlimab, belrestotug, and nelistotug. These drugs are designed to enhance the immune system’s ability to fight cancer cells.

This interventional study is randomized with a parallel assignment model and no masking. Its primary purpose is treatment, focusing on assessing the novel combinations’ effectiveness against NSCLC.

The study began on October 14, 2022, with an anticipated completion date in August 2025. The primary completion date is yet to be reached, and the last update was submitted on August 14, 2025. These dates are crucial for tracking the study’s progress and expected outcomes.

The update on this study could influence GSK and iTeos Therapeutics’ stock performance, as positive results may boost investor confidence and market value. This study’s progress is particularly relevant in the competitive landscape of cancer immunotherapy, where advancements can significantly impact market dynamics.

The study is ongoing, and further details are available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1